Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2020-11-30 Board/Management Inform…
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Board/Management Information Classification · 95% confidence The document lists the members of the board of directors and their roles and functions, including committee memberships. It does not contain financial data, earnings, or report content. It is an announcement related to the company's board structure and management. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on board composition, confirming it is not a full report or other filing type.
2020-11-30 English
APPOINTMENT AND RESIGNATION OF NON-EXECUTIVE DIRECTORS
Board/Management Information Classification · 95% confidence The document is an announcement from CStone Pharmaceuticals regarding the appointment and resignation of non-executive directors. It details the biography of the newly appointed director, the resignation of the previous director, and related governance information. There are no financial statements, earnings data, or regulatory filings about financial performance. The content focuses solely on changes in the company's board of directors. Therefore, this document fits the category of Board/Management Information (MANG). The document length and detail support this classification with high confidence.
2020-11-30 English
VOLUNTARY ANNOUNCEMENT-UPDATE ON PROPOSED PLANNING OF SIGNIFICANT EVENT BY CONTROLLING SHAREHOLDER
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Yanzhou Coal Mining Company Limited regarding the update on a significant event, specifically the closing of a merger agreement between its controlling shareholder Yankuang Group and Shandong Energy Group. The text includes details about the merger closing date and reassures shareholders about the controlling shareholder status remaining unchanged. The document is relatively short (2684 characters) and serves as an announcement of a corporate event rather than a detailed report or financial statement. It does not contain financial data, audit information, or detailed management discussion. It is not a full merger filing (like a DEFM14A or SC TO-*), but rather an update on a significant event related to the controlling shareholder. This fits best under the category of a Regulatory Filing (RNS), which is a fallback for miscellaneous regulatory announcements that do not fit other categories. It is not a full M&A filing or merger proxy statement, nor a capital/financing update since it is about a strategic reorganization update. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2020-11-30 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2020-11-27 English
VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES THE RESULTS OF GEMSTONE-302 SUGEMALIMAB HAS THE POTENTIAL TO PROVIDE A NEW TREATMENT OPTION FOR PATIENTS WITH ADVANCED NSCLC
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding positive clinical trial results (GEMSTONE-302 study) for their drug sugemalimab in treating advanced non-small cell lung cancer (NSCLC). It includes detailed clinical data, study design, endpoints, and quotes from company executives and investigators. The document is not a financial report, earnings release, or regulatory filing about financials. It is not an announcement of a report publication but a standalone announcement of clinical trial results. There is no indication of board changes, voting results, or capital changes. The content focuses on clinical trial outcomes and drug development progress, which is typical for a voluntary announcement related to clinical or product development updates. Given the nature and content, this fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like earnings or annual reports.
2020-11-23 English
VOLUNTARY ANNOUNCEMENT - GLOBAL STRATEGIC PARTNERSHIP BETWEEN CSTONE AND EQRX TAKES EFFECT FOLLOWING EARLY TERMINATION OF HSR WAITING PERIOD
Capital/Financing Update Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding the global strategic partnership with EQRx following the early termination of the HSR waiting period. It details the licensing agreement, upfront payments, milestone payments, and rights related to drug development and commercialization. The content focuses on a corporate transaction and partnership update rather than financial results, regulatory filings, or management changes. It does not contain financial statements or detailed financial analysis, nor is it a report or presentation. The document is an announcement about a capital/financing-related strategic partnership and licensing deal, which fits best under Capital/Financing Update (CAP). The document length (7645 characters) and content confirm it is not a brief report publication announcement or a regulatory filing. Therefore, the classification is CAP with high confidence.
2020-11-20 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.